MARKET

TCDA

TCDA

Tricida
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.36
-0.35
-2.99%
Closed 16:52 09/18 EDT
OPEN
11.83
PREV CLOSE
11.71
HIGH
11.99
LOW
11.20
VOLUME
655.25K
TURNOVER
--
52 WEEK HIGH
44.30
52 WEEK LOW
9.54
MARKET CAP
568.56M
P/E (TTM)
-2.4089
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Should You Take Comfort From Insider Transactions At Tricida, Inc. (NASDAQ:TCDA)?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Simply Wall St. · 09/11 19:08
TRICIDA ALERT: Bragar Eagel & Squire, P.C. is Investigating Tricida, Inc. on Behalf of Tricida Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Tricida, Inc. (NADSAQ: TCDA) on behalf of Tricida stockholders. Our investigation concerns whether Tricida has violated the federal securities
GlobeNewswire · 09/01 01:52
EQUITY ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Tricida, Inc. TCDA
NEW YORK, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces investigation of potential securities claims on behalf of shareholders of Tricida, Inc. (NASDAQ: TCDA) resulting from allegations that Tricida may have issued materially misleading business information
GlobeNewswire · 08/29 16:00
TCDA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Tricida, Inc. Investors of Investigation and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tricida, Inc. ("Tricida" or "the Company") (NASDAQ: TCDA). Investors who purchased Tricida securities are encouraged to obtain additional information and assist
PR Newswire · 08/27 19:45
Tricida Suffers Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Tricida suffers setback on Veverimer front. CohBar advances its Phase 1b trial for NASH treatment.
Seeking Alpha - Article · 08/26 05:43
Goldman Sachs Downgrades Tricida to Neutral, Lowers Price Target to $10
Goldman Sachs analyst Graig Suvannavejh downgrades Tricida (NASDAQ:TCDA) from Buy to Neutral and lowers the price target from $25 to $10.
Benzinga · 08/25 15:59
Why Tricida's Stock Is Trading Lower Today
Tricida (NASDAQ: TCDA) shares are trading lower on Monday after the company received a Complete Response Letter from the FDA for its New Drug Application for Veverimer.
Benzinga · 08/24 19:43
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD
Business Wire · 08/24 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TCDA stock price target is 23.33 with a high estimate of 40.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 152
Institutional Holdings: 43.25M
% Owned: 86.42%
Shares Outstanding: 50.05M
TypeInstitutionsShares
Increased
51
4.96M
New
33
276.21K
Decreased
25
3.85M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
Klaus Veitinger
President/Chief Executive Officer/Director
Gerrit Klaerner
Chief Financial Officer/Executive Vice President
Geoffrey Parker
Executive Vice President/General Counsel/Secretary
Robert McKague
Executive Vice President
Susannah Cantrell
Executive Vice President
Dawn Parsell
Senior Vice President - Finance/Chief Accounting Officer
Marc Cobo
Senior Vice President
Edward Hejlek
Independent Director
Robert Alpern
Independent Director
David Bonita
Independent Director
Sandra Coufal
Independent Director
Kathryn Falberg
Independent Director
David Hirsch
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average TCDA stock price target is 23.33 with a high estimate of 40.00 and a low estimate of 10.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TCDA
Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tricida Inc stock information, including NASDAQ:TCDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCDA stock methods without spending real money on the virtual paper trading platform.